Kolgelier, ServetDemir, Nazlim AktugInkaya, Ahmet CagkanSumer, SuaOzcimen, SerapDemir, Lutfi SaltukPehlivan, Fatma Seher2024-02-232024-02-2320151735-143X1735-3408https://doi.org/10.5812/hepatmon.30655https://hdl.handle.net/20.500.12452/17084Background: Hepatologists have studied serologic markers of liver injury for decades. Annexins are a prominent group of such markers and annexin A2 (AnxA2) is one of the best characterized annexins. AnxA2 inhibits HBV polymerase among other functions. Its expression is up-regulated in regenerative hepatocytes. Objectives: To determine if serum AnxA2 level has a role in estimating liver damage in chronic HBV infection and investigate whether AnxA2 levels correlate with hepatic fibrosis. Patients and Methods: This study included 173 patients with chronic hepatitis B (CHB) and 51 healthy controls. Liver fibrosis was graded histologically on liver biopsy samples. Blood samples were taken from patients during biopsy and serum AnxA2 levels were measured with ELISA. Results: In a group of adult patients with CHB, AnxA2 values were far higher than those of the control group (P = 0.001). When we assessed AnxA2 levels based on fibrosis stages, serum AnxA2 levels of patients with early stage fibrosis (stages 1 - 3) were significantly higher than those of patients with advanced stage fibrosis (stages 4 - 5; P = 0.001). Conclusions: AnxA2 is a useful biomarker for early stage fibrosis in patients with CHB.eninfo:eu-repo/semantics/openAccessAnnexin A2Hepatitis BChronicLiver FibrosisBiological MarkerArticle1510265870362-s2.0-84990306234Q4WOS:000368272800005Q310.5812/hepatmon.30655